The US Food and Drug Administration (FDA) approved 126 innovator and biosimilar drugs in 2024, significantly lower than the ...
Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the ...
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as ...
Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...
Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...
Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...
Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients: Indianapolis Wednesday, February 26, 2025, 17:00 Hrs [IST] Eli Lilly and Company announ ...
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...
The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...